Valuation Takeda Pharmaceutical Company Limited Sao Paulo
Stocks
TAKP34
BRTAKPBDR006
Pharmaceuticals
|
Market Closed -
Sao Paulo
09:00:07 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 99.07 BRL | -.--% |
|
-.--% | +19.13% |
| 09-30 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 09-30 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 9,010,510 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 0.7% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 12,917,027 | 12,712,695 | 12,406,930 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 151.77% | -1.58% | -2.41% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 44.7x | 28.4x | 23.1x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.21x | 1.21x | 1.2x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 12.68x | 0.5x | 1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.92x | 1.88x | 1.83x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.75x | 2.65x | 2.52x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 10.1x | 9.18x | 8.59x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 27.5x | 21.1x | 17.8x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 18.3x | 18.1x | 16.9x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.46% | 5.52% | 5.92% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 215.8 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.62% | 3.69% | 3.82% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 126.3 | 198.7 | 243.8 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 162% | 105% | 88.5% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,703,619 | 4,794,178 | 4,920,458 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,283,686 | 1,384,728 | 1,444,038 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 470,109 | 603,263 | 697,746 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 196,495 | 322,724 | 383,352 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,906,517 | 3,702,186 | 3,396,421 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,643.00 | 5,643.00 | 5,643.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 410.8B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- TAKP34 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
